Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity

被引:1
|
作者
da Silva, Joao Guilherme Lino [1 ,2 ]
Goncalves, Ana Alice Maia [1 ]
Oliveira, Liliam Teixeira [3 ]
Garcia, Giani Martins [3 ]
Batista, Mauricio Azevedo [1 ]
de Mendonca, Ludmila Zanandreis [1 ]
Viana, Kelvinson Fernandes [1 ]
Oliveira Sant'Ana, Rita de Cassia [1 ]
Melo Junior, Otoni Alves de Oliveira [1 ]
Silveira-Lemos, Denise [4 ]
Dutra, Walderez Ornelas [1 ,5 ]
Martins-Filho, Olindo Assis [6 ]
Galdino, Alexsandro Sobreira [7 ]
de Moura, Sandra Aparecida Lima [8 ]
Mosqueira, Vanessa Carla Furtado [3 ]
Giunchetti, Rodolfo Cordeiro [1 ,5 ]
机构
[1] Univ Fed Minas Gerais UFMG, Lab Cell Cell Interact, Dept Morphol, Biol Sci Inst, BR-30161970 Belo Horizonte, Brazil
[2] Univ Fed Ouro Preto, Nucleus Res Biol Sci NUPEB, BR-3540000 Ouro Preto, Brazil
[3] Univ Fed Ouro Preto, Sch Pharm, Lab Pharmaceut & Nanotechnol LDGNano, BR-3540000 Ouro Preto, Brazil
[4] Fundacao Oswaldo Cruz, Rene Rachou Res Ctr, Integrated Res Grp Biomarkers, BR-30190009 Belo Horizonte, Brazil
[5] Natl Inst Sci & Technol Trop Dis, INCT DT, BR-40110060 Salvador, Brazil
[6] Fundacao Oswaldo Cruz, Rene Rachou Res Ctr, Lab Diag & Monitoring Biomarkers, BR-30190009 Belo Horizonte, Brazil
[7] Fed Univ Sao Joao Del Rei UFSJ, Lab Microorganism Biotechnol, Midwest Campus, BR-35501296 Divinopolis, Brazil
[8] Univ Fed Ouro Preto, Inst Exact & Biol Sci, Lab Biomat & Expt Pathol, Lab Expt Pathophysiol, BR-35402136 Ouro Preto, Brazil
关键词
visceral leishmaniasis; submicrometric particles; vaccine; polymeric nanoparticles; CHITOSAN; NANOPARTICLES; ADJUVANTS; PROTECTION; CANDIDATE; IMPACT;
D O I
10.3390/vaccines11081309
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent studies suggest that the association of antigens in microparticles increases the antiLeishmania vaccine immunogenicity. This study aims to investigate the in situ effect of the adjuvant performance consisting of chitosan-coated poly(D,L-lactic) acid submicrometric particles (SMP) and analyze the inflammatory profile and toxicity. Two formulations were selected, SMP1, containing poly(D,L-lactide) (PLA) 1% wt/v and chitosan 1% wt/v; and SMP2, containing PLA 5% wt/v and chitosan 5% wt/v. After a single dose of the unloaded SMP1 or SMP2 in mice, the SMPs promoted cell recruitment without tissue damage. In addition, besides the myeloperoxidase (MPO) activity having demonstrated similar results among the analyzed groups, a progressive reduction in the levels of N-acetyl- b-D-glucosaminidase (NAG) until 72 h was observed for SMPs. While IL-6 levels were similar among all the analyzed groups along the kinetics, only the SMPs groups had detectable levels of TNF-ff. Additionally, the Leishmania braziliensis antigen was encapsulated in SMPs (SMP1Ag and (SMPAg)-Ag-2), and mice were vaccinated with three doses. The immunogenicity analysis by flow cytometry demonstrated a reduction in NK (CD3(-) CD49(+)) cells in all the SMPs groups, in addition to impairment in the T cells subsets (CD3(+)CD4(+)) and CD3(+)CD8(+)) and B cells (CD19(+)) of the SMP2 group. The resulting data demonstrate that the chitosan-coated SMP formulations stimulate the early events of an innate immune response, suggesting their ability to increase the immunogenicity of co-administered Leishmania antigens.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Polymeric nanogels as vaccine delivery systems
    Ferreira, Silvia A.
    Gama, Francisco M.
    Vilanova, Manuel
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2013, 9 (02) : 159 - 173
  • [22] Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis
    Thakur, Ankita
    Kaur, Harpreet
    Kaur, Sukhbir
    PARASITOLOGY INTERNATIONAL, 2015, 64 (01) : 70 - 78
  • [23] The FML-vaccine (Leishmune®) against canine visceral leishmaniasis:: A transmission blocking vaccine
    Saraiva, EM
    Barbosa, AD
    Santos, FN
    Borja-Cabrera, GP
    Nico, D
    Souza, LOP
    Mendes-Aguiara, CD
    de Souzaa, EP
    Fampa, P
    Parra, LE
    Menz, I
    Dias, JG
    de Oliveira, SM
    Palatnik-de-Sousa, CB
    VACCINE, 2006, 24 (13) : 2423 - 2431
  • [24] Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development
    Volpedo, Greta
    Pacheco-Fernandez, Thalia
    Bhattacharya, Parna
    Oljuskin, Timur
    Dey, Ranadhir
    Gannavaram, Sreenivas
    Satoskar, Abhay R.
    Nakhasi, Hira L.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [25] Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL)
    Borja-Cabrera, G. P.
    Santos, F. B.
    Picillo, E.
    Gravino, A. E.
    Manna, L.
    Palatnik-de-Sousa, C. B.
    VACCINE, 2008,
  • [26] Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis
    Das, Amrita
    Ali, Nahid
    EXPERT REVIEW OF VACCINES, 2012, 11 (07) : 783 - 785
  • [27] Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis
    Moreno, Javier
    FRONTIERS IN VETERINARY SCIENCE, 2019, 6
  • [28] Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis
    Breton, M
    Tremblay, MJ
    Ouellette, M
    Papadopoulou, B
    INFECTION AND IMMUNITY, 2005, 73 (10) : 6372 - 6382
  • [29] Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis
    Lari, Alireza
    Lari, Niloofar
    Biabangard, Atefeh
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2022, 28 (01)
  • [30] DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control
    Kumar, A.
    Samant, M.
    PARASITE IMMUNOLOGY, 2016, 38 (05) : 273 - 281